Market overview
The global insulin delivery market is worth USD 16.8 bn in 2026 and is forecast to reach USD 36.3 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Pumps and consumables is the largest by product segment.
| Scope | Insulin delivery devices and consumables: pens, pumps and infusion sets, syringes and needles, patch and jet injectors. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 15.5 bn |
| Value 2026 | USD 16.8 bn |
| Value 2036 | USD 36.3 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 4,318 million units |
| Volume 2036 | 8,870 million units |
| Average price 2026 | USD 3.89 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Insulin Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 16.8 bn |
| 2027 | USD 18.2 bn |
| 2028 | USD 19.6 bn |
| 2029 | USD 21.2 bn |
| 2030 | USD 22.9 bn |
| 2031 | USD 24.7 bn |
| 2032 | USD 26.7 bn |
| 2033 | USD 28.8 bn |
| 2034 | USD 31.1 bn |
| 2035 | USD 33.6 bn |
| 2036 | USD 36.3 bn |
Insulin Delivery market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Insulin pens | 24.0% | 19.7% | USD 4.0 bn | 5.9% |
| Pumps and consumables | 52.0% | 59.2% | USD 8.7 bn | 9.4% |
| Syringes and needles | 14.0% | 8.6% | USD 2.4 bn | 2.9% |
| Patch and jet injectors | 10.0% | 12.5% | USD 1.7 bn | 10.4% |
By patient
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Type 1 | 38.0% | 41.3% | USD 6.4 bn | 8.9% |
| Type 2 | 52.0% | 49.2% | USD 8.7 bn | 7.4% |
| Gestational and other | 10.0% | 9.5% | USD 1.7 bn | 7.4% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Home | 74.0% | 76.9% | USD 12.4 bn | 8.4% |
| Hospitals | 18.0% | 15.5% | USD 3.0 bn | 6.4% |
| Long-term care | 8.0% | 7.6% | USD 1.3 bn | 7.4% |
By technology level
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Conventional manual devices | 62.0% | 48.0% | USD 10.4 bn | 5.3% |
| Connected pens and smart devices | 20.0% | 28.0% | USD 3.4 bn | 11.7% |
| Automated insulin delivery | 18.0% | 24.0% | USD 3.0 bn | 11.2% |
By distribution
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacy | 52.0% | 48.0% | USD 8.7 bn | 7.1% |
| Hospital pharmacy | 18.0% | 16.0% | USD 3.0 bn | 6.7% |
| Online and equipment suppliers | 30.0% | 36.0% | USD 5.0 bn | 10.0% |
Top 25 countries for insulin delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 78.5% of 2026 revenue and the 25 countries below together hold 94.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 6.4 bn | 38.0% | USD 13.0 bn | 7.4% |
| 2 | China | USD 1.3 bn | 8.0% | USD 4.0 bn | 11.4% |
| 3 | Germany | USD 1.0 bn | 6.0% | USD 1.9 bn | 6.5% |
| 4 | Japan | USD 841 mn | 5.0% | USD 1.4 bn | 5.3% |
| 5 | United Kingdom | USD 757 mn | 4.5% | USD 1.4 bn | 6.5% |
| 6 | France | USD 673 mn | 4.0% | USD 1.2 bn | 6.3% |
| 7 | India | USD 673 mn | 4.0% | USD 2.2 bn | 12.5% |
| 8 | Italy | USD 505 mn | 3.0% | USD 944 mn | 6.5% |
| 9 | Canada | USD 505 mn | 3.0% | USD 1.0 bn | 7.3% |
| 10 | Brazil | USD 505 mn | 3.0% | USD 1.1 bn | 8.3% |
| 11 | Spain | USD 267 mn | 1.6% | USD 537 mn | 7.2% |
| 12 | Mexico | USD 234 mn | 1.4% | USD 588 mn | 9.7% |
| 13 | South Korea | USD 234 mn | 1.4% | USD 468 mn | 7.2% |
| 14 | Australia | USD 234 mn | 1.4% | USD 468 mn | 7.2% |
| 15 | Russia | USD 200 mn | 1.2% | USD 403 mn | 7.2% |
| 16 | Turkey | USD 200 mn | 1.2% | USD 505 mn | 9.7% |
| 17 | Netherlands | USD 166 mn | 1.0% | USD 334 mn | 7.2% |
| 18 | Saudi Arabia | USD 166 mn | 1.0% | USD 421 mn | 9.7% |
| 19 | Indonesia | USD 166 mn | 1.0% | USD 505 mn | 11.7% |
| 20 | Egypt | USD 133 mn | 0.8% | USD 334 mn | 9.7% |
| 21 | Poland | USD 133 mn | 0.8% | USD 269 mn | 7.3% |
| 22 | Switzerland | USD 133 mn | 0.8% | USD 269 mn | 7.3% |
| 23 | Pakistan | USD 133 mn | 0.8% | USD 403 mn | 11.7% |
| 24 | Argentina | USD 101 mn | 0.6% | USD 200 mn | 7.1% |
| 25 | Taiwan | USD 101 mn | 0.6% | USD 200 mn | 7.1% |
| Rest of world | USD 1.0 bn | 6.0% | USD 2.2 bn | 8.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Medtronic
- Insulet
- Tandem Diabetes Care
- Novo Nordisk
- Sanofi
Group 2: Regional and specialist players
- Ypsomed
- Embecta
- Becton Dickinson
- Roche
- Eli Lilly
- Owen Mumford
- Terumo
Group 3: Emerging and niche players
- Sooil Development
- Medtrum
- Beta Bionics
- Sequel Med Tech
- Diabeloop
- EOFlow
- Dana Diabecare
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the insulin delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by product, by patient, by end user, by technology level, by distribution. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the insulin delivery market?
The global insulin delivery market is estimated at USD 15.5 bn in 2025 and USD 16.8 bn in 2026.
How fast will the insulin delivery market grow?
It is forecast to reach USD 36.3 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 19.5 bn.
Which country is the largest market for insulin delivery?
United States is the largest market by revenue at USD 6.4 bn in 2026, 38.0% of the global total. The three largest countries together hold 52.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 12.5% a year from 2026 to 2036.
Which insulin delivery segment is largest?
In the by product split, Pumps and consumables is the largest segment with 52.0% of 2026 revenue.
Who are the leading insulin delivery companies?
Global leaders include Medtronic, Insulet, Tandem Diabetes Care, Novo Nordisk.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Downstream ProcessingUSD 16.6 bn · 10.5% CAGR
- Antibody Drug ConjugatesUSD 16.5 bn · 14.5% CAGR
- Next Generation SequencingUSD 16.4 bn · 13.0% CAGR
- Rare Cardiovascular Disease TherapeuticsUSD 16.1 bn · 9.0% CAGR
- Fill FinishUSD 17.6 bn · 9.0% CAGR
- Surgical RoboticsUSD 17.7 bn · 14.0% CAGR
- Metered Dose InhalerUSD 17.9 bn · 5.0% CAGR
- Pharmaceutical FiltrationUSD 15.8 bn · 9.0% CAGR